Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
KYTX Kyverna Therapeutics Inc.
- Stocks
- Healthcare
- NASDAQ: KYTX
Price (delayed)
$2.32
Market cap
$100.27M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.38
Enterprise value
$49.78M
We are a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. Our goal is to bring disease-modifying therapeutic benefits to patients suffering from
Highlights
Kyverna Therapeutics's EPS has soared by 95% YoY
Kyverna Therapeutics's debt has decreased by 36% YoY and by 16% QoQ
The net income has dropped by 92% year-on-year and by 14% since the previous quarter
Kyverna Therapeutics's quick ratio has plunged by 57% YoY and by 14% from the previous quarter
Key stats
What are the main financial stats of KYTX
Market
Valuations
Earnings
Shares outstanding
43.22M
Market cap
$100.27M
Enterprise value
$49.78M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.45
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$160.65M
Net income
-$145.42M
EBIT
-$145.3M
EBITDA
-$140.42M
Free cash flow
-$135.3M
Per share
Balance sheet
Liquidity
EPS
-$3.38
EPS diluted
-$3.38
Free cash flow per share
-$3.13
Book value per share
$5.18
Revenue per share
$0
TBVPS
$6.03
Total assets
$260.66M
Total liabilities
$36.65M
Debt
$6.94M
Equity
$224.01M
Working capital
$214.36M
Debt to equity
0.03
Current ratio
7.44
Quick ratio
7.31
Net debt/EBITDA
0.36
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-45.9%
Return on equity
-51.6%
Return on invested capital
-73.7%
Return on capital employed
-63.9%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
KYTX stock price
How has the Kyverna Therapeutics stock price performed over time
Intraday
6.42%
1 week
9.95%
1 month
26.78%
1 year
-84.79%
YTD
-37.97%
QTD
20.21%
Financial performance
How have Kyverna Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$160.65M
Net income
-$145.42M
Gross margin
N/A
Net margin
N/A
KYTX's operating income has shrunk by 100% YoY and by 13% QoQ
The net income has dropped by 92% year-on-year and by 14% since the previous quarter
Price vs fundamentals
How does KYTX's price correlate with its fundamentals
Growth
What is Kyverna Therapeutics's growth rate over time
Valuation
What is Kyverna Therapeutics stock price valuation
P/E
N/A
P/B
0.45
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Kyverna Therapeutics's EPS has soared by 95% YoY
KYTX's equity is down by 38% year-on-year and by 16% since the previous quarter
The price to book (P/B) is 36% lower than the last 4 quarters average of 0.7
Efficiency
How efficient is Kyverna Therapeutics business performance
The company's return on equity has shrunk by 146% YoY and by 28% QoQ
The company's return on assets has shrunk by 135% YoY and by 26% QoQ
KYTX's ROIC has shrunk by 50% YoY and by 11% QoQ
Dividends
What is KYTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for KYTX.
Financial health
How did Kyverna Therapeutics financials performed over time
Kyverna Therapeutics's quick ratio has plunged by 57% YoY and by 14% from the previous quarter
The current ratio has plunged by 57% YoY and by 14% from the previous quarter
Kyverna Therapeutics's debt is 97% lower than its equity
KYTX's equity is down by 38% year-on-year and by 16% since the previous quarter
Kyverna Therapeutics's debt has decreased by 36% YoY and by 16% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.